1. Home
  2. MPB vs SDGR Comparison

MPB vs SDGR Comparison

Compare MPB & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mid Penn Bancorp

MPB

Mid Penn Bancorp

HOLD

Current Price

$31.07

Market Cap

797.6M

Sector

Finance

ML Signal

HOLD

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

HOLD

Current Price

$12.02

Market Cap

856.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPB
SDGR
Founded
1868
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
797.6M
856.7M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
MPB
SDGR
Price
$31.07
$12.02
Analyst Decision
Buy
Buy
Analyst Count
1
8
Target Price
$37.00
$21.13
AVG Volume (30 Days)
109.8K
1.2M
Earning Date
04-22-2026
05-06-2026
Dividend Yield
2.82%
N/A
EPS Growth
N/A
45.14
EPS
2.55
N/A
Revenue
N/A
$255,869,000.00
Revenue This Year
$30.84
$6.11
Revenue Next Year
$9.45
$7.69
P/E Ratio
$12.26
N/A
Revenue Growth
N/A
23.29
52 Week Low
$22.50
$11.11
52 Week High
$35.22
$27.63

Technical Indicators

Market Signals
Indicator
MPB
SDGR
Relative Strength Index (RSI) 41.40 40.57
Support Level $28.12 $11.11
Resistance Level $31.75 $13.36
Average True Range (ATR) 0.82 0.62
MACD -0.10 0.06
Stochastic Oscillator 29.52 25.23

Price Performance

Historical Comparison
MPB
SDGR

About MPB Mid Penn Bancorp

Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Share on Social Networks: